A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 96 (5) , 1250-1261
Abstract
No abstract availableKeywords
Funding Information
- Mayo Clinic
This publication has 15 references indexed in Scilit:
- An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19JAMA, 2021
- A Randomized Trial of Convalescent Plasma in Covid-19 Severe PneumoniaNew England Journal of Medicine, 2021
- Managing Patients in the COVID-19 PandemicMayo Clinic Proceedings: Innovations, Quality & Outcomes, 2021
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Telemedicine Consultations and Follow-up of Patients With COVID-19Mayo Clinic Proceedings, 2020
- A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital SettingMayo Clinic Proceedings, 2020
- Clinical Guidance and the Delivery of Care for Patients With Coronavirus Disease 2019Mayo Clinic Proceedings, 2020
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)Clinical Infectious Diseases, 2020